NKTCL is a common kind of malignant lymphoma, and usually develops in the nasal cavity but can also occur in extranasal sites, either as a primary extranasal or disseminated disease (Takeuchi et al., 2014). A recent study demonstrated that the level of GSN is significantly decreased in serums of advanced NKTCL patients (Zhou et al., 2016). However, the potential effects of GSN on NK/T-cell lymphoma cells and molecular mechanisms remain unclear.